Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Gates, Drug Firms Partner For TB Drugs

by Lisa M. Jarvis
July 2, 2012 | A version of this story appeared in Volume 90, Issue 27

Backed by roughly $20 million in funding from the Bill & Melinda Gates Foundation, seven pharmaceutical companies and four research institutions will work together to discover new drugs to treat tuberculosis. The drug partners in the TB Drug Accelerator—Abbott Laboratories, AstraZeneca, Bayer Healthcare, Eli Lilly & Co., GlaxoSmithKline, Merck & Co., and Sanofi—will screen compound libraries and share data among one another and with government and academic institutions. TBDA has set a goal of finding five new preclinical drug candidates that shorten the treatment time for TB within the next five years.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.